{"id":131084,"date":"2026-07-09T18:27:44","date_gmt":"2026-07-10T00:27:44","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=131084"},"modified":"2026-07-09T18:27:44","modified_gmt":"2026-07-10T00:27:44","slug":"how-much-weight-can-you-lose-on-retatrutide-trial-results-explained","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/how-much-weight-can-you-lose-on-retatrutide-trial-results-explained\/","title":{"rendered":"How Much Weight Can You Lose on Retatrutide? Trial Results Explained"},"content":{"rendered":"<p class=\"font-claude-response-body break-words whitespace-normal\">Retatrutide has produced some of the largest weight loss of any drug in development, reaching roughly 24% in mid-stage trials and climbing toward 30% in later, longer studies, approaching what bariatric surgery achieves. It&#8217;s a triple agonist, and this level of weight loss is the main reason it&#8217;s considered one of the most promising obesity drugs in the pipeline. Retatrutide is investigational and not FDA approved. Here&#8217;s what the trials actually showed and how to interpret the numbers.<\/p>\n<h3 class=\"text-text-100 mt-3 -mb-1 text-[1.125rem] font-bold\">The Phase 2 Result That Started the Buzz<\/h3>\n<p class=\"font-claude-response-body break-words whitespace-normal\">Retatrutide first drew major attention with a phase 2 trial published in the <a class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\">New England Journal of Medicine<\/a> in 2023, which studied it in adults with obesity and found that the highest dose produced about 24% average weight loss at 48 weeks. That figure was striking because it exceeded what approved drugs like semaglutide (around 15%) and tirzepatide (up to about 21%) had shown, positioning retatrutide as potentially the most powerful option yet. Just as notably, the weight loss hadn&#8217;t plateaued at 48 weeks, hinting that longer treatment could push it higher.<\/p>\n<h3 class=\"text-text-100 mt-3 -mb-1 text-[1.125rem] font-bold\">The Phase 3 Numbers<\/h3>\n<p class=\"font-claude-response-body break-words whitespace-normal\">That hint proved accurate. Topline results from the pivotal phase 3 trial (TRIUMPH-1), announced in 2026, showed even larger weight loss over a longer 80-week period. At the highest dose, participants lost up to about 28% of their body weight, and a meaningful share (over 40%) lost at least 30%. In a study extension following people with more severe obesity out to 104 weeks, average weight loss reached up to about 30%.<\/p>\n<div class=\"overflow-x-auto w-full px-2 mb-6\">\n<table class=\"min-w-full border-collapse text-sm leading-[1.7] whitespace-normal\">\n<thead class=\"text-left\">\n<tr>\n<th class=\"text-text-100 border-b-0.5 border-[hsl(var(--border-300)\/0.6)] py-2 pr-4 align-top font-bold\" scope=\"col\">Trial<\/th>\n<th class=\"text-text-100 border-b-0.5 border-[hsl(var(--border-300)\/0.6)] py-2 pr-4 align-top font-bold\" scope=\"col\">Dose<\/th>\n<th class=\"text-text-100 border-b-0.5 border-[hsl(var(--border-300)\/0.6)] py-2 pr-4 align-top font-bold\" scope=\"col\">Approximate weight loss<\/th>\n<th class=\"text-text-100 border-b-0.5 border-[hsl(var(--border-300)\/0.6)] py-2 pr-4 align-top font-bold\" scope=\"col\">Duration<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">Phase 2<\/td>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">Highest<\/td>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">About 24%<\/td>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">48 weeks<\/td>\n<\/tr>\n<tr>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">Phase 3 (TRIUMPH-1)<\/td>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">Highest<\/td>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">Up to about 28%<\/td>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">80 weeks<\/td>\n<\/tr>\n<tr>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">Phase 3 extension<\/td>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">Highest<\/td>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">Up to about 30%<\/td>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">104 weeks<\/td>\n<\/tr>\n<tr>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">Phase 3 (lower dose)<\/td>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">4 mg<\/td>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">About 19%<\/td>\n<td class=\"border-b-0.5 border-[hsl(var(--border-300)\/0.3)] py-2 pr-4 align-top\">80 weeks<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p class=\"font-claude-response-body break-words whitespace-normal\">Even the lower 4 mg dose produced about 19% weight loss, which is competitive with the strongest approved drugs, while offering a gentler option.<\/p>\n<h3 class=\"text-text-100 mt-3 -mb-1 text-[1.125rem] font-bold\">What &#8220;Bariatric-Level&#8221; Means<\/h3>\n<p class=\"font-claude-response-body break-words whitespace-normal\">Weight loss near 30% is significant because it enters territory previously associated mainly with weight-loss surgery. For context, procedures like gastric bypass often produce weight loss in roughly the 25% to 35% range. A medication reaching similar numbers would represent a real shift in what&#8217;s possible without surgery. Consider a hypothetical patient who wasn&#8217;t a candidate for or didn&#8217;t want surgery: a drug delivering surgery-like weight loss would open a genuinely new option for them, which is the promise driving interest in retatrutide.<\/p>\n<h3 class=\"text-text-100 mt-3 -mb-1 text-[1.125rem] font-bold\">A Note on the Numbers<\/h3>\n<p class=\"font-claude-response-body break-words whitespace-normal\">As with any trial, the exact figure depends on how it&#8217;s measured. The roughly 28% reflects results when people stay on treatment as intended, while a broader analysis counting everyone (including those who stopped) shows a somewhat lower figure closer to 25%. Both are impressive. It&#8217;s also worth remembering these later results are topline announcements, with full peer-reviewed publication still to come, so some details may be refined.<\/p>\n<h3 class=\"text-text-100 mt-3 -mb-1 text-[1.125rem] font-bold\">Frequently Asked Questions<\/h3>\n<h4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\">How much weight can you actually lose on retatrutide?<\/h4>\n<p class=\"font-claude-response-body break-words whitespace-normal\">In trials, the highest dose produced about 24% weight loss over 48 weeks (phase 2) and up to about 28% over 80 weeks (phase 3), reaching up to about 30% in a longer extension for people with more severe obesity. Lower doses produced correspondingly less, around 19% at the 4 mg dose.<\/p>\n<h4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\">Is retatrutide the most effective weight-loss drug?<\/h4>\n<p class=\"font-claude-response-body break-words whitespace-normal\">It has shown some of the highest weight loss of any drug in development, approaching bariatric-surgery levels. Whether it&#8217;s definitively the &#8220;most effective&#8221; depends on final phase 3 data and comparisons, but it&#8217;s among the front-runners.<\/p>\n<h4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\">Is retatrutide available to lose weight now?<\/h4>\n<p class=\"font-claude-response-body break-words whitespace-normal\">No. Retatrutide is investigational and not FDA approved, available only through clinical trials, though a regulatory submission is anticipated. TrimRx offers currently available options like compounded semaglutide and tirzepatide and brand GLP-1 medications instead.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\">To focus on what you can actually start with today, you can <a class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\" href=\"https:\/\/trimrx.com\/quiz\">explore the options available to you now<\/a> with a licensed provider.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal\"><em>This information is for educational purposes and is not medical advice. Retatrutide is investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Retatrutide has produced some of the largest weight loss of any drug in development, reaching roughly 24% in mid-stage trials and climbing toward 30%&#8230;<\/p>\n","protected":false},"author":7,"featured_media":93233,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[12],"tags":[],"class_list":["post-131084","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weight-loss"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/131084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=131084"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/131084\/revisions"}],"predecessor-version":[{"id":131085,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/131084\/revisions\/131085"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93233"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=131084"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=131084"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=131084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}